Is Beta Bionics, Inc. (BBNX) Halal?

NASDAQ Healthcare United States $478M
✗ NOT HALAL
Confidence: 90/100
Beta Bionics, Inc. (BBNX) is Not Halal under AAOIFI Standard 21. While the debt ratio of 1.6% is acceptable, the cash and interest-bearing securities ratio of 46.5% exceeds the 30% threshold. Beta Bionics, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 1.6%
/ 30%
46.5%
/ 30%
4.2%
/ 30%
10.9%
/ 5%
✗ NOT HALAL
DJIM 1.6%
/ 33%
46.5%
/ 33%
4.2%
/ 33%
10.9%
/ 5%
✗ NOT HALAL
MSCI 2.2%
/ 33%
66.7%
/ 33%
6.1%
/ 33%
10.9%
/ 5%
✗ NOT HALAL
S&P 1.6%
/ 33%
46.5%
/ 33%
4.2%
/ 33%
10.9%
/ 5%
✗ NOT HALAL
FTSE 2.2%
/ 33%
66.7%
/ 33%
6.1%
/ 50%
10.9%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-1.81
P/B Ratio
1.7
EV/EBITDA
-3.8
EV: $266M
Revenue
$100M
Growth: 57.1%
Current Ratio
8.7

Profitability

Gross Margin 55.4%
Operating Margin -50.2%
Net Margin -73.0%
Return on Equity (ROE) -40.3%
Return on Assets (ROA) -18.7%

Cash Flow & Balance Sheet

Operating Cash Flow-$51M
Free Cash Flow-$56M
Total Debt$7M
Debt-to-Equity2.5
Current Ratio8.7
Total Assets$329M

Price & Trading

Last Close$11.52
50-Day MA$13.13
200-Day MA$19.69
Avg Volume1.3M
52-Week Range
$8.89
$32.71

About Beta Bionics, Inc. (BBNX)

CEO
Mr. Sean T. Saint PE
Employees
420
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NASDAQ
Market Cap
$478M
Currency
USD

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Beta Bionics, Inc. (BBNX) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Beta Bionics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Beta Bionics, Inc.'s debt ratio?

Beta Bionics, Inc.'s debt ratio is 1.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.2%.

What are Beta Bionics, Inc.'s key financial metrics?

Beta Bionics, Inc. has a market capitalization of $478M, and revenue of $100M. The company maintains a gross margin of 55.4% and a net margin of -73.0%. Return on equity stands at -40.3%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.